Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Thyroid Carcinoma, Anaplastic

• NEO- and Adjuvant Targeted Therapy in Braf-mutated Anaplastic Cancer of the Thyroid (NEO-ATACT Study)
• DETERMINE Trial Treatment Arm 5: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.
• Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
• PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer
• Vudalimab for the Treatment of Locally Advanced or Metastatic Anaplastic Thyroid Cancer or Hurthle Cell Thyroid Cancer
• Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
• The Efficacy and Safety of HLX208 in Advanced Anaplastic Thyroid Cancer (ATC) With BRAF V600 Mutation
• Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer
• Dabrafenib and Trametinib Combination as a Neoadjuvant Strategy in BRAF-positive Anaplastic Thyroid Cancer
• Pembrolizumab and Lenvatinib/Chemotherapy for Poorly Differentiated/Anaplastic Thyroid Cancer
• Pembrolizumab, Dabrafenib, and Trametinib Before Surgery for the Treatment of BRAF-Mutated Anaplastic Thyroid Cancer
• Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
• Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)
• Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer
• Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors
• Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study
• Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid Cancer
• Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer
• Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer
• LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
• Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer
• Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer
• Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer
• Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer
• CUDC-907 Treatment in People With Metastatic and Locally Advanced Thyroid Cancer
• A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
• Phase II Study Assessing the Efficacy and Safety of Lenvatinib for Anaplastic Thyroid Cancer
• Pembrolizumab in Anaplastic/Undifferentiated Thyroid Cancer
• A Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)
• A Trial of Adalimumab Combined to Chemotherapy and Radiotherapy in Patients With Anaplastic Thyroid Cancers
• Ceritinib in Mutation and Oncogene Directed Therapy in Thyroid Cancer
• A Phase II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer
• Inolitazone Dihydrochloride and Paclitaxel in Treating Patients With Advanced Anaplastic Thyroid Cancer
• Fosbretabulin or Placebo in Combination With Carboplatin/Paclitaxel in Anaplastic Thyroid Cancer
• A Phase I/II Trial of Crolibulin (EPC2407) Plus Cisplatin in Adults With Solid Tumors With a Focus on Anaplastic Thyroid Cancer (ATC)
• Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer
• Avastin and Doxorubicin Postoperatively for Patients With Anaplastic Thyroid Cancer
• Pemetrexed + Paclitaxel in Patients With Recurrent/Advanced Thyroid Cancer
• Phase II Trial of Sorafenib (Nexavar) in Patients With Advanced Thyroid Cancer
• Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer
• A Phase 1/2 Study of CS7017, an Oral PPARγ Agonist, in Combination With Paclitaxel
• Study of Combretastatin and Paclitaxel/Carboplatin in the Treatment of Anaplastic Thyroid Cancer
• Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer
• Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma
• Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer
• Induction Chemotherapy Using Doxorubicin and Cisplatin Followed by Combretastatin A4 Phosphate and Radiation Therapy in Treating Patients With Newly Diagnosed Regionally Advanced Anaplastic Thyroid Cancer
• Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer
• Combretastatin A4 Phosphate in Treating Patients With Advanced Anaplastic Thyroid Cancer
• Chemotherapy Plus Radiation Therapy in Treating Patients With Previously Untreated Thyroid Cancer